STMN1 and breast carcinoma: High levels of stathmin decreased the sensitivity of breast cancer cell lines to paclitaxel and vincristine [24] and knock-down of stathmin by siRNA increased the sensitivity to paclitaxel in both breast [25] and prostate cells [27].